Pages that link to "Q40463923"
Jump to navigation
Jump to search
The following pages link to The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. (Q40463923):
Displaying 50 items.
- Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned (Q26738514) (← links)
- Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies (Q26744113) (← links)
- Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib (Q26750696) (← links)
- Guidelines for the management of myeloproliferative neoplasms (Q26778326) (← links)
- Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development (Q26779947) (← links)
- New Therapeutic Approaches in Polycythemia Vera (Q26795677) (← links)
- The evolving treatment paradigm in myelofibrosis (Q27021968) (← links)
- Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors (Q28073296) (← links)
- Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera (Q28729862) (← links)
- A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms (Q30992878) (← links)
- New drugs for the treatment of myelofibrosis (Q33389330) (← links)
- Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis (Q33391880) (← links)
- Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib (Q33402522) (← links)
- Emerging drugs for myelofibrosis (Q33404574) (← links)
- Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial (Q33405985) (← links)
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. (Q33410346) (← links)
- Practical management of patients with myelofibrosis receiving ruxolitinib (Q33410649) (← links)
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea (Q33411637) (← links)
- Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients (Q33413428) (← links)
- Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms (Q33417217) (← links)
- A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis (Q33420095) (← links)
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial (Q33421596) (← links)
- Managing patients with myelofibrosis and low platelet counts (Q33432406) (← links)
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial (Q33432637) (← links)
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis (Q33436345) (← links)
- Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202 (Q33436442) (← links)
- Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (Q33436685) (← links)
- Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population (Q33436870) (← links)
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial (Q33440361) (← links)
- Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years (Q33517074) (← links)
- Experience with ruxolitinib in the treatment of polycythaemia vera (Q33605624) (← links)
- Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls (Q33843390) (← links)
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia (Q34146512) (← links)
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations (Q34150008) (← links)
- Targeting myeloproliferative neoplasms with JAK inhibitors (Q34159701) (← links)
- Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial (Q34162867) (← links)
- Pharmacological management of essential thrombocythemia (Q34344384) (← links)
- Modest activity of pomalidomide in patients with myelofibrosis and significant anemia (Q34512203) (← links)
- Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease (Q34625390) (← links)
- Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy (Q35032345) (← links)
- Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia (Q35188877) (← links)
- Exercise facilitators and barriers following participation in a community-based exercise and education program for cancer survivors (Q35229212) (← links)
- Profile of pomalidomide and its potential in the treatment of myelofibrosis (Q35427915) (← links)
- Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. (Q35565555) (← links)
- IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F (Q35835653) (← links)
- Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey (Q35938283) (← links)
- Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib (Q36305314) (← links)
- Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review (Q36529881) (← links)
- Ruxolitinib for myelofibrosis (Q36604028) (← links)
- An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. (Q36708989) (← links)